The full Eli Lilly (LLY) reaction history

LLY news moved a median of +0.07% by the close. Every LLY news event with the realized, point-in-time move the market made — the same measurement, headline by headline. Back to the LLY overview →

Half of the 396 LLY news events with a measured close landed between -0.84% and +0.95%; 53% closed up.

By year and event type

LLY reaction counts across 4 years.

Event type2026202520242023Total
Press release951169337341
SEC filing · Form 8-K5913128
SEC filing · Form 10-Q23319
SEC filing · Form 10-K11103
SEC filing · Form 11-K11103
SEC filing · Form DEF11103
SEC filing · Form DEFA14A11103
SEC filing · Form PRE11103
SEC filing · Form SD11103
SEC filing · Form S-3ASR01001
All types10813511539397

Counts from the full measured window for LLY, not just the free rows below — every event type we have labeled, year by year.

Archive pages

Older LLY news pages.

Page 1 is the LLY overview; pages 2–8 carry the rest of the measured list.

The 10 most recent LLY reactions.

DateHeadlineEventSource5-minTo close
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular diseasePress releasePR Newswire-0.65%-0.31%
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetesPress releasePR Newswire+0.59%-2.88%
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes studyPress releasePR Newswire-0.65%-0.31%
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitisPress releasePR Newswire+0.06%-2.48%
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparisonPress releasePR Newswire+0.34%+0.15%
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetesPress releasePR Newswire+0.06%-2.48%
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparisonPress releasePR Newswire+0.34%+0.15%
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICsPress releasePR Newswire+0.69%+0.39%
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areataPress releasePR Newswire+0.69%+0.39%
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetesPress releasePR Newswire+0.80%+2.00%

387 more LLY reactions are behind a free account. Create one to see all 397 measured LLY events — the same point-in-time reactions, every headline.

See all 397 LLY events →

No credit card · 100 free credits/mo

Keep exploring

More LLY: earnings → · analyst actions → · SEC filings → · LLY overview →

Other Health Care names, measured the same way

TickerEventsMedian 30-min% positive
Johnson & Johnson (JNJ)2,000++0.06%56%
UnitedHealth Group (UNH)2,000+-0.03%48%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.